A secondary RET mutation in the activation loop conferring resistance to vandetanib-Reference-Cited by-同舟云学术

A secondary RET mutation in the activation loop conferring resistance to vandetanib

Published:2018-02-12 Issue:1 Volume:9 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Nakaoku Takashi,Kohno Takashi,Araki Mitsugu,Niho Seiji,Chauhan Rakhee,Knowles Phillip P.,Tsuchihara Katsuya,Matsumoto Shingo,Shimada Yoko,Mimaki Sachiyo,Ishii Genichiro,Ichikawa Hitoshi,Nagatoishi Satoru,Tsumoto Kouhei,Okuno Yasushi,Yoh Kiyotaka,McDonald Neil Q.,Goto Koichi

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/s41467-018-02994-7.pdf

Reference38 articles.

1. Shaw, A. T., Hsu, P. P., Awad, M. M. & Engelman, J. A. Tyrosine kinase gene rearrangements in epithelial malignancies. Nat. Rev. Cancer 13, 772–787 (2013).

2. Pasche, B. & Grant, S. C. Non-small cell lung cancer and precision medicine: a model for the incorporation of genomic features into clinical trial design. JAMA 311, 1975–1976 (2014).

3. Camidge, D. R., Pao, W. & Sequist, L. V. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat. Rev. Clin. Oncol. 11, 473–481 (2014).

4. Choi, Y. L. et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med. 363, 1734–1739 (2010).

5. Mulligan, L. M. RET revisited: expanding the oncogenic portfolio. Nat. Rev. Cancer 14, 173–186 (2014).

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fundamentals and recent advances in the evaluation and management of medullary thyroid carcinoma;Molecular and Cellular Endocrinology;2024-10

2. Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: “Shadows and Fogs”;Cancers;2024-08-19

3. Novel therapeutic strategies targeting bypass pathways and mitochondrial dysfunction to combat resistance to RET inhibitors in NSCLC;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-08

4. Medullary Thyroid Cancer: Molecular Drivers and Immune Cellular Milieu of the Tumour Microenvironment—Implications for Systemic Treatment;Cancers;2024-06-22

5. Recent progress of small-molecule of RET inhibitors against Non-small cell lung cancer;AAPS Open;2024-06-17